In a report released today, Annabel Samimy from Stifel Nicolaus maintained a Buy rating on Phathom Pharmaceuticals (PHAT – Research Report), ...

Stifel Nicolaus analyst Alex Thompson CFA maintained a Buy rating on Viridian Therapeutics (VRDN – Research Report) today and set a price ...

Walmart’s latest brand and logo update has left some social media users baffled. On Jan. 13, the company announced in a press release on its website that it was launching a “comprehensive ...

Stifel Financial Corp (NYSE:SF). has announced a revision to its executive compensation structure, according to a recent SEC filing. On Monday, the Compensation Committee of the Board of Directors ...

Stifel Financial (SF) could be a solid choice for investors given the company's remarkably improving earnings outlook. While the stock has been a strong performer lately, this trend might continue ...

Eagle Financial Services, Inc. (OTCQX: EFSI) (the "Company"), parent company of Bank of Clarke, today announced the pricing of its previously announced underwritten public offering of 1,562,500 shares ...

Apple supplier Skyworks Solutions saw its stock drop nearly 25% Thursday as the semiconductor firm said that it's losing ...

Good afternoon, and welcome to SiTime's fourth quarter 2024 financial results conference call. At this time, all participants ...

Unitholders of record on February 3, 2025 will receive cash distributions payable on February 10, 2025. Mackenzie Investments Logo (CNW Group/Mackenzie Financial Corporation) ...

High-return investments are financial opportunities that offer the potential for significant profits, often exceeding the average market returns. These investments can include a range of options ...

Stifel's focus on self-help and growth opportunities suggests that while the overall sector outlook is cautious, there may still be potential for strategic investment moves within the industry.

Stifel has initiated coverage of Cytokinetics (NASDAQ:CYTK) with a buy rating, citing its drug aficamten. The bank noted the stock was "out of favor" in the wake of a "controversial" deal with ...